Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 3220 results found since Jan 2013.

Progress in Topical siRNA Delivery Approaches for Skin Disorders.
Abstract The topical application of therapeutic agent has shown promising efficacy in the treatment of skin disorders. The siRNA based therapies have been used for treatment of various disorders including skin diseases. The topical delivery of siRNA based therapies has opened new perspectives for the treatment of skin disorders. The use of siRNA is limited due to the rapid degradation and poor cellular uptake. Also, the stratum corneum, the top layer of skin is the major barrier for the delivery of topical agents. There is unmet need for efficient topical formulation that will deliver the siRNA to the site of acti...
Source: Current Pharmaceutical Design - September 10, 2015 Category: Drugs & Pharmacology Authors: Aldawsari M, Chougule MB, Babu RJ Tags: Curr Pharm Des Source Type: research

Exosomes: Natural Carriers for siRNA Delivery.
Abstract Various cells of the human physiological system have the capability to release extracellular vesicles (EVs) involved in intercellular transport of proteins and nucleic acids. Exosomes are a subtype of extracellular vesicles having their origin through endocytic pathway. While being involved in intercellular transport of macromolecules, exosomes, due to their presence in several body fluids, can also be utilized as a system to commute RNA molecules and proteins in the body. Recent advances in gene therapy have provided a new outlook in disease therapeutics by modulation of gene expression using oligonucleo...
Source: Current Pharmaceutical Design - October 23, 2015 Category: Drugs & Pharmacology Authors: Kumar L, Verma S, Vaidya B, Gupta V Tags: Curr Pharm Des Source Type: research

Pharmacokinetics and Biodistribution of Recently-Developed siRNA Nanomedicines.
Abstract Small interfering RNA (siRNA) is a promising drug candidate, expected to have broad therapeutic potentials toward various diseases including viral infections and cancer. With recent advances in bioconjugate chemistry and carrier technology, several siRNA-based drugs have advanced to clinical trials. However, most cases address local applications or diseases in the filtering organs, reflecting remaining challenges in systemic delivery of siRNA. The difficulty in siRNA delivery is in large part due to poor circulation stability and unfavorable pharmacokinetics and biodistribution profiles of siRNA. This rev...
Source: Advanced Drug Delivery Reviews - December 10, 2015 Category: Drugs & Pharmacology Authors: Park J, Park J, Pei Y, Xu J, Yeo Y Tags: Adv Drug Deliv Rev Source Type: research

Biokinetic studies of non-complexed siRNA versus nano-sized PEI F25-LMW/siRNA polyplexes following intratracheal instillation into mice
Publication date: 16 March 2016 Source:International Journal of Pharmaceutics, Volume 500, Issues 1–2 Author(s): Jens Lipka, Manuela Semmler-Behnke, Alexander Wenk, Jana Burkhardt, Achim Aigner, Wolfgang Kreyling Successful gene therapy requires stability and sufficient bioavailability of the applied drug at the site of action. In the case of RNA interference (RNAi), non-viral vectors play a promising role for delivering intact siRNA molecules. We selected a low molecular weight polyethyleneimine (PEI F25-LMW) and investigated the biokinetics of PEI F25-LMW/siRNA polyplexes in comparison to non-complexed siRNA mo...
Source: International Journal of Pharmaceutics - January 31, 2016 Category: Drugs & Pharmacology Source Type: research

PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness.
In conclusion, the right balance between cytotoxicity and siRNA effectiveness has been found with the transfection of lipoplexes coated with 20% of Ceramide-PEG2000. This new nanovector could have a high potential against multiple mucosal diseases, such as human papillomavirus-induced genital lesions. PMID: 27593989 [PubMed - as supplied by publisher]
Source: European Journal of Pharmaceutical Sciences - August 31, 2016 Category: Drugs & Pharmacology Authors: Lechanteur A, Furst T, Evrard B, Delvenne P, Hubert P, Piel G Tags: Eur J Pharm Sci Source Type: research

Inhaled powder formulation of naked siRNA using spray drying technology with l-leucine as dispersion enhancer
In this study, siRNA was co-spray dried with mannitol and l-leucine, the latter being a dispersion enhancer. To the best of our knowledge, this is the first time that siRNA in its naked form was formulated into an inhalable dry powder using spray drying technology. The aerosol performance of the powder was evaluated by Next Generation Impactor (NGI). The presence of l-leucine in the formulation could improve the aerosolization of siRNA-containing powders. Results from the X-ray photoelectron spectroscopy (XPS) suggested that l-leucine was enriched on the particle surface and promote powder dispersion. Among the different s...
Source: International Journal of Pharmaceutics - September 6, 2017 Category: Drugs & Pharmacology Source Type: research

Transdermal anti-nuclear kappaB siRNA therapy for atopic dermatitis using a combination of two kinds of functional oligopeptide
Publication date: 5 May 2018 Source:International Journal of Pharmaceutics, Volume 542, Issues 1–2 Author(s): Hisako Ibaraki, Takanori Kanazawa, Yuuki Takashima, Hiroaki Okada, Yasuo Seta Nucleic acid-based targeting of nuclear factor kappaB (NF-κB) is gaining attention as a treatment option for skin diseases like atopic dermatitis (AD). Transdermal administration improves patient quality of life because of non-invasive; however, siRNA delivery into the skin can be challenging owing to the barrier of tight junctions in the granular layer. Therefore, we aimed to develop a delivery system of siRNA for topical skin applic...
Source: International Journal of Pharmaceutics - March 23, 2018 Category: Drugs & Pharmacology Source Type: research

Characterization of modified mesoporous silica nanoparticles as vectors for siRNA delivery
Publication date: Available online 21 February 2018Source: Asian Journal of Pharmaceutical SciencesAuthor(s): Anna Slita, Anna Egorova, Eudald Casals, Anton Kiselev, Jessica M. RosenholmAbstractGene therapy using siRNA molecules is nowadays considered as a promising approach. For successful therapy, development of a stable and reliable vector for siRNA is crucial. Non-viral and non-organic vectors like mesoporous silica nanoparticles (MSN) are associated with lack of most viral vector drawbacks, such as toxicity, immunogenicity, but also generally a low nucleic acid carrying capacity. To overcome this hurdle, we here modif...
Source: Asian Journal of Pharmaceutical Sciences - July 5, 2018 Category: Drugs & Pharmacology Source Type: research

Nanovehicle-based small interfering RNA (siRNA) delivery for therapeutic purposes: a new molecular approach in the pharmacogenomics.
Abstract RNA interference (RNAi) is a process for regulating the gene expression in which small interfering RNAs (siRNAs) silence target genes. siRNA-based therapy as a new molecular treatment approach, offers therapeutic prospects for many common diseases such as cancer and cardiovascular disorders. Nevertheless, the efficacy of siRNA delivery has, so far, remained a challenging issue. This is due to their easy degradation through the circulation system and the difficulties in the intracellular delivery to specific tissues where they silence the target genes. There have been many efforts to develop suitable, safe...
Source: Current Clinical Pharmacology - July 9, 2018 Category: Drugs & Pharmacology Authors: Akhtari J, Tafazoli A, Mehrad-Majd H, Mahrooz A Tags: Curr Clin Pharmacol Source Type: research

Current non-viral siRNA delivery systems as a promissing treatment of skin diseases.
CONCLUSION: The treatment of skin diseases based on topical delivery of siRNA, which act by inhibiting the expression of target transcripts, offers many potential therapeutic advantages for suppressing genes into the skin. PMID: 30084329 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Rosa J, Suzuki I, Kravicz M, Caron A, Pupo AV, Praca FG, Bentley MVLB Tags: Curr Pharm Des Source Type: research

Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
CONCLUSION: siRNA therapeutic potential to preclude liver IRI can be improved by a better knowledge of what molecules to target and by using more efficient delivery strategies. PMID: 30084326 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - August 7, 2018 Category: Drugs & Pharmacology Authors: Marinho HS, Marcelino P, Soares H, Corvo ML Tags: Curr Pharm Des Source Type: research

Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
In this study, AuNPs capped with polyethylenimine (PEI) and PEGylated anisamide (a ligand known to target the sigma receptor) have been developed to produce a range of positively charged anisamide-targeted PEGylated AuNPs (namely Au-PEI-PEG-AA). The anisamide-targeted AuNPs effectively complexed siRNA via electrostatic interaction, and the resultant complex (Au110-PEI-PEG5000-AA.siRNA) illustrated favourable physicochemical characteristics, including particle size, surface charge, and stability. In vitro, anisamide-targeted AuNPs selectively bound to human prostate cancer PC-3 cells, inducing efficient endosomal escape of ...
Source: European Journal of Pharmaceutics and Biopharmaceutics - February 16, 2019 Category: Drugs & Pharmacology Authors: Luan X, Rahme K, Cong Z, Wang L, Zou Y, He Y, Yang H, Holmes JD, O'Driscoll CM, Guo J Tags: Eur J Pharm Biopharm Source Type: research

Cholic acid-based mixed micelles as siRNA delivery agents for gene therapy
In this study, we demonstrate the use of lipids as co-surfactants for the preparation of mixed micelles to improve the siRNA delivery of cholic acid-based block copolymers. Poly(allyl glycidyl ether) (PAGE) and poly(ethylene glycol) (PEG) were polymerized on the surface of cholic acid to afford a star-shaped block copolymer with four arms (CA-PAGE-b-PEG)4. The allyl groups of PAGE were functionalized to bear primary or tertiary amines and folic acid was grafted onto the PEG chain end to increase cell uptake. (CA-PAGE-b-PEG)4 functionalized with either primary or tertiary amines show high siRNA complexation with close to 10...
Source: International Journal of Pharmaceutics - January 26, 2020 Category: Drugs & Pharmacology Source Type: research

A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids
Drug Deliv. 2021 Dec;28(1):1055-1066. doi: 10.1080/10717544.2021.1931560.ABSTRACTGiven the maturation of small-interfering RNA (siRNA) techniques with nanotechnology, and because overexpression of human programmed death-ligand 1 (PD-L1) is crucial for T cell inactivation and immunosuppression of the tumor microenvironment, application of siRNA-PD-L1 has demonstrated positive progress in preclinical studies; however, the limited penetration of this compound into solid tumors remains a challenge. To decrease PD-L1 expression and increase the penetration efficacy of solid tumors, we synthesized a novel tumor-microenvironment-...
Source: Drug Delivery - June 3, 2021 Category: Drugs & Pharmacology Authors: Jiaolin Wen Neng Qiu Zejiang Zhu Peng Bai Mengshi Hu Wenyan Qi Yan Liu Ailin Wei Lijuan Chen Source Type: research